Altamira Therapeutics Ltd. (CYTOF)
OID · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.4M | -1.2M | -81K | |
| Operating Income | -7.5M | -18.9M | -6.6M | -6.9M |
| Net Income | -18.7M | -27.8M | -4.3M | -8.5M |
| Diluted EPS | $-563.52 | $-428.90 | $-16.47 | $-2.99 |